Topiroxostat: Difference between revisions
CSV import |
CSV import |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{Short description|A xanthine oxidase inhibitor used in the treatment of gout}} | |||
{{Drugbox | |||
| verifiedfields = changed | |||
| verifiedrevid = 477002123 | |||
| image = Topiroxostat.svg | |||
| image_size = 200px | |||
| image_alt = | |||
| image_caption = Chemical structure of Topiroxostat | |||
}} | |||
'''Topiroxostat''' is a [[xanthine oxidase]] inhibitor used primarily in the management of [[gout]] and [[hyperuricemia]]. It is a non-purine selective inhibitor that reduces the production of [[uric acid]] by inhibiting the activity of xanthine oxidase, an enzyme involved in the conversion of [[hypoxanthine]] to [[xanthine]] and xanthine to uric acid. | |||
Topiroxostat | |||
== | ==Mechanism of Action== | ||
Topiroxostat is | Topiroxostat works by selectively inhibiting the enzyme xanthine oxidase. This enzyme is responsible for the oxidation of hypoxanthine to xanthine and xanthine to uric acid, which is the final step in the catabolism of [[purines]] in humans. By inhibiting this enzyme, topiroxostat effectively reduces the production of uric acid, thereby lowering serum uric acid levels and preventing the formation of [[uric acid crystals]] in joints and tissues. | ||
== | ==Clinical Use== | ||
Topiroxostat is indicated for the treatment of hyperuricemia in patients with gout. It is particularly useful in patients who are intolerant to other xanthine oxidase inhibitors such as [[allopurinol]]. The drug is administered orally and is typically well-tolerated by patients. | |||
== | ==Side Effects== | ||
Common side effects of topiroxostat include [[nausea]], [[diarrhea]], and [[headache]]. Some patients may experience [[liver function test]] abnormalities, and it is recommended to monitor liver function during treatment. Rarely, hypersensitivity reactions may occur. | |||
== | ==Pharmacokinetics== | ||
Topiroxostat | Topiroxostat is absorbed orally and undergoes hepatic metabolism. It is excreted primarily in the urine. The drug has a half-life that allows for convenient dosing schedules, typically once or twice daily. | ||
== | ==Development and Approval== | ||
Topiroxostat was developed as an alternative to existing treatments for hyperuricemia and gout, with a focus on providing a selective inhibition of xanthine oxidase. It has been approved for use in several countries and continues to be studied for its efficacy and safety in various populations. | |||
==Related pages== | |||
* [[Gout]] | * [[Gout]] | ||
* [[Hyperuricemia]] | * [[Hyperuricemia]] | ||
* [[Xanthine oxidase]] | |||
* [[Allopurinol]] | |||
* [[Febuxostat]] | |||
[[Category:Xanthine oxidase inhibitors]] | [[Category:Xanthine oxidase inhibitors]] | ||
[[Category: | [[Category:Gout treatments]] | ||
<gallery> | |||
File:Topiroxostat.svg|Topiroxostat | |||
</gallery> | |||
Latest revision as of 01:25, 20 February 2025
A xanthine oxidase inhibitor used in the treatment of gout
| Topiroxostat | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Topiroxostat is a xanthine oxidase inhibitor used primarily in the management of gout and hyperuricemia. It is a non-purine selective inhibitor that reduces the production of uric acid by inhibiting the activity of xanthine oxidase, an enzyme involved in the conversion of hypoxanthine to xanthine and xanthine to uric acid.
Mechanism of Action[edit]
Topiroxostat works by selectively inhibiting the enzyme xanthine oxidase. This enzyme is responsible for the oxidation of hypoxanthine to xanthine and xanthine to uric acid, which is the final step in the catabolism of purines in humans. By inhibiting this enzyme, topiroxostat effectively reduces the production of uric acid, thereby lowering serum uric acid levels and preventing the formation of uric acid crystals in joints and tissues.
Clinical Use[edit]
Topiroxostat is indicated for the treatment of hyperuricemia in patients with gout. It is particularly useful in patients who are intolerant to other xanthine oxidase inhibitors such as allopurinol. The drug is administered orally and is typically well-tolerated by patients.
Side Effects[edit]
Common side effects of topiroxostat include nausea, diarrhea, and headache. Some patients may experience liver function test abnormalities, and it is recommended to monitor liver function during treatment. Rarely, hypersensitivity reactions may occur.
Pharmacokinetics[edit]
Topiroxostat is absorbed orally and undergoes hepatic metabolism. It is excreted primarily in the urine. The drug has a half-life that allows for convenient dosing schedules, typically once or twice daily.
Development and Approval[edit]
Topiroxostat was developed as an alternative to existing treatments for hyperuricemia and gout, with a focus on providing a selective inhibition of xanthine oxidase. It has been approved for use in several countries and continues to be studied for its efficacy and safety in various populations.
Related pages[edit]
-
Topiroxostat
